Theravance Biopharma Ownership | Who Owns Theravance Biopharma?


OverviewForecastRevenueFinancialsChartTranscripts

Theravance Biopharma Ownership Summary


Theravance Biopharma is owned by 14.11% institutional investors, 5.82% insiders, and 80.07% retail investors. Madison avenue partners, lp is the largest institutional shareholder, holding 19.40% of TBPH shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.29% of its assets in Theravance Biopharma shares.

TBPH Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockTheravance Biopharma14.11%5.82%80.07%
SectorHealthcare Stocks 57.39%9.93%32.68%
IndustryBiotech Stocks 68.48%9.65%21.87%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Madison avenue partners, lp9.51M19.40%$89.50M
Weiss asset management lp7.46M15.21%$70.17M
Newtyn management4.76M9.70%$44.77M
Blackrock3.78M7.83%$32.06M
Blackrock funding, inc. /de3.71M7.57%$34.93M
Irenic capital management lp2.76M5.63%$25.98M
Vanguard group2.01M4.10%$18.92M
Park west asset management1.79M3.66%$16.87M
State street1.27M2.62%$10.75M
Oasis management1.12M2.28%$10.50M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Madison avenue partners, lp9.51M9.48%$89.50M
Newtyn management4.76M7.80%$44.77M
Irenic capital management lp2.76M2.79%$25.98M
Oasis management1.12M2.22%$10.50M
Weiss asset management lp7.46M1.44%$70.17M
Park west asset management1.79M1.36%$16.87M
Camber capital management lp1.00M0.22%$9.41M
Corton capital33.35K0.18%$313.79K
Tang capital management262.90K0.16%$2.47M
Virtus etf advisers35.43K0.14%$333.36K

Top Buyers

HolderShares% AssetsChange
Newtyn management4.76M7.80%258.34K
Ubs group174.25K0.00%143.49K
Dimensional fund advisors lp553.71K0.00%95.30K
Millennium management192.84K0.00%80.14K
D. e. shaw833.94K0.01%69.18K

Top Sellers

HolderShares% AssetsChange
Baupost group llc/ma---4.20M
Pictet asset management sa---684.89K
Blackrock3.78M0.00%-428.18K
Bank of montreal /can/---160.14K
Hrt financial lp---153.42K

New Positions

HolderShares% AssetsChangeValue
Two sigma advisers, lp33.90K0.00%33.90K$287.47K
Corton capital33.35K0.18%33.35K$313.79K
Townsquare capital14.47K0.00%14.47K$136.16K
Proshare advisors12.67K0.00%12.67K$119.24K
Clearalpha technologies lp11.59K0.07%11.59K$109.02K

Sold Out

HolderChange
Capital performance advisors llp-5.00
Nelson, van denburg & campbell wealth management group-13.00
Srs capital advisors-57.00
Covestor-62.00
Riggs asset managment-114.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 202446-61.98%6,919,684-84.88%140.16%23-56.60%11-73.17%
Sep 30, 2024121-9.02%45,773,807-2.84%931.00%53-22.06%41-8.89%
Jun 30, 20241329.09%47,111,010-1.79%970.99%6828.30%44-4.35%
Mar 31, 20241211.68%47,969,701-1.71%991.02%5315.22%46-4.17%
Dec 31, 20231193.48%48,802,581-4.01%981.05%464.55%4817.07%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv1.13M2.29%11.10K
Vanguard US Total Market Shares ETF1.07M2.15%-
iShares Russell 2000 ETF941.66K1.90%-8.14K
Pictet Biopharmaceutical Mother652.30K1.32%-349.81K
Vanguard Institutional Extnd Mkt Idx Tr521.63K1.05%11.93K
State St Russell Sm/Mid Cp® Indx NL Cl C371.08K0.75%-
Fidelity Small Cap Index363.33K0.73%-6.80K
iShares Russell 2000 Value ETF331.03K0.67%-
State St Russell Sm/Mid Cp® Indx SL Cl I329.25K0.66%-41.83K
CREF Stock R1308.81K0.62%-26.42K

Recent Insider Transactions


DateNameRoleActivityValue
Jan 21, 2025Farnum Rhonda SVP, COMM & MEDICAL AFFAIRSSell$36.00K
Nov 11, 2024Farnum Rhonda SVP, COMM & MEDICAL AFFAIRSSell$36.00K
Jul 10, 2024Farnum Rhonda SVP, COMM & MEDICAL AFFAIRSSell$36.00K
May 01, 2024Samaha Eli-Buy$8.75M
May 01, 2024Samaha Eli-Buy$4.37M

Insider Transactions Trends


DateBuySell
2025 Q1-1
2024 Q4-1
2024 Q3-1
2024 Q22-
2024 Q1-1

TBPH Ownership FAQ


Who Owns Theravance Biopharma?

Theravance Biopharma shareholders are primarily institutional investors at 14.11%, followed by 5.82% insiders and 80.07% retail investors. The average institutional ownership in Theravance Biopharma's industry, Biotech Stocks , is 68.48%, which Theravance Biopharma falls below.

Who owns the most shares of Theravance Biopharma?

Theravance Biopharma’s largest shareholders are Madison avenue partners, lp (9.51M shares, 19.40%), Weiss asset management lp (7.46M shares, 15.21%), and Newtyn management (4.76M shares, 9.70%). Together, they hold 44.30% of Theravance Biopharma’s total shares outstanding.

Does Blackrock own Theravance Biopharma?

Yes, BlackRock owns 7.83% of Theravance Biopharma, totaling 3.78M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 32.06M$. In the last quarter, BlackRock decreased its holdings by -428K shares, a -10.17% change.

Who is Theravance Biopharma’s biggest shareholder by percentage of total assets invested?

Madison avenue partners, lp is Theravance Biopharma’s biggest shareholder by percentage of total assets invested, with 9.48% of its assets in 9.51M Theravance Biopharma shares, valued at 89.5M$.

Who is the top mutual fund holder of Theravance Biopharma shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Theravance Biopharma shares, with 2.29% of its total shares outstanding invested in 1.13M Theravance Biopharma shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools